Aravive to Participate in Upcoming Virtual Investor Conferences in September

Rhea-AI Summary

Aravive, Inc. (Nasdaq: ARAV) announced its participation in two virtual investor conferences in September 2020. The presentations will occur at the Cantor Fitzgerald Global Healthcare Conference on September 15 at 3:20 p.m. ET and the H.C. Wainwright 22nd Annual Global Investment Conference on September 16 at 1:00 p.m. ET. The company will also discuss its lead therapeutic, AVB-500, which targets the GAS6-AXL signaling pathway. A recent Phase 1b trial showed promising results, with 100% clinical benefit in a specific patient cohort. Archived replays of the presentations will be available for 90 days.

HOUSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following two virtual investor conferences in September:

• Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 15, 2020, at 3:20 p.m. ET
• H.C. Wainwright 22^nd Annual Global Investment Conference on Wednesday, September 16, 2020, at 1:00 p.m. ET

Live webcasts and audio archives of the presentations will be available at http://ir.aravive.com. Archived replays of the webcasts will be available for 90 days following the presentations.

About Aravive
Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive’s lead therapeutic, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth. Aravive recently successfully completed a Phase 1b trial of AVB-500 in platinum resistant ovarian cancer and selected 15 mg/kg as the dose for the next potential pivotal trial. Analysis of all safety data to date showed that AVB-500 has been generally well-tolerated with no dose-limiting toxicities or unexpected safety signals. While the Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mg/kg cohort experienced clinical benefit, with 1 complete response, 2 partial responses, and 2 stable disease. The Company also intends to initiate a Phase 1b/Phase 2 trial of AVB-500 in clear cell renal cell carcinoma later this year. For more information, please visit www.aravive.com.

Contacts:
Media:
Sheryl Seapy, W2O
sseapy@w2ogroup.com
(949) 903-4750

Investors:
Luke Heagle, W2O 
lheagle@w2ogroup.com
(910) 726-1372

 

FAQ

What are the dates and times for Aravive's upcoming investor conferences?

Aravive will present at the Cantor Fitzgerald Global Healthcare Conference on September 15, 2020, at 3:20 p.m. ET and the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 1:00 p.m. ET.

How did AVB-500 perform in the recent Phase 1b trial?

In the Phase 1b trial of AVB-500 for platinum resistant ovarian cancer, all 5 patients in the 15 mg/kg cohort experienced clinical benefits, including 1 complete response, 2 partial responses, and 2 stable disease cases.

Where can I find the webcasts of Aravive's presentations?

Live webcasts and audio archives of Aravive's presentations can be found at http://ir.aravive.com, with archived replays available for 90 days.

What is the focus of Aravive as a company?

Aravive is a clinical-stage oncology company focused on developing transformative therapeutics to halt the progression of life-threatening diseases, particularly in cancer treatment.

What are the future plans for AVB-500?

Aravive plans to initiate a Phase 1b/Phase 2 trial of AVB-500 in clear cell renal cell carcinoma later this year.